Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are bo

U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech,

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress

Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility

Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than avera

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress a

Precigen just received an FDA "platform technology designation" for AdenoVerse, something that valid

Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12,

B. Riley Securities analyst Yuan Zhi initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rati

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoV

Precigen, Inc. (NASDAQ: PGEN - Get Free Report) shares hit a new 52-week high during mid-day trading

Designation has the potential to accelerate development of current and future therapies built on Pre

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report)

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand

Legal and General Group Plc purchased a new stake in Precigen, Inc. (NASDAQ: PGEN) during the undefi

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook art

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurre

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's f

Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 bill

Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a B

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respirat

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Cisco Inc (NASDAQ: CSCO) beat expectations and raised guidance with $15.84B revenue and $1.06 EPS. S

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.02) per share which met the analyst consensu

Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medic

The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w

Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating esti

Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainer

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu

Shares of Navan Inc (NASDAQ: NAVN) spiked in pre-market trading on better-than-expected Q4 results.

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.01) per share which beat the analyst consens

 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the adv